2024.12.19 -

Caliway to Present CBL-514 Phase 2b Study Results for Subcutaneous Fat Reduction at IMCAS 2025 in Paris

The findings from the CBL-0204 Phase 2b clinical trial have been selected for presentation at IMCAS, the premier global congress in aesthetic medicine. The data will be highlighted in both the 2025 focus session on advances in fat reduction therapies and further detailed in the Non-surgical Body Contouring session through an oral presentation.

2024.12.11 -

Caliway Announces Successful Study Results from CBL-0204, a CBL-514 Phase 2b Study for Reducing Abdominal Subcutaneous Fat, Met All Primary and Secondary Efficacy Endpoints

CBL-514 Phase 2b study for subcutaneous fat reduction (CBL-0204 Phase 2b study) met all the primary and secondary efficacy endpoints in the FAS (Full analysis set) and PP (Per-protocol) population analysis.

Caliway Biopharmaceuticals Included in FTSE TWSE Taiwan Eight Industries and Mid-Cap 100 Indices

Caliway is proud to announce its inclusion in the FTSE TWSE Taiwan Mid-Cap 100 Index and the FTSE TWSE Taiwan Eight Industries Index.

2024.11.12 -

Caliway Announced EMA Orphan Drug Designation Granted to CBL-514 for Dercum’s Disease Treatment

CBL-514 is the first and only drug to receive EMA Orphan Drug Designation for Dercum’s disease treatment.

2024.10.23 -

Caliway Completed CBL-514 Phase 2b Study (CBL-0205) for Subcutaneous Fat Reduction

The first and only lipolytic injectable for large area – CBL-514’s last Phase 2b study has been completed

2024.10.02 -

Caliway Successfully Lists on Taipei Exchange Following IPO

Caliway is pleased to announce the successful completion of its initial public offering (IPO) and up-listing from the Emerging Stock Market to the Taipei Exchange (TWSE-6919).

2024.08.26 -

Caliway Announces the Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum's Disease

Caliway announced that the subject recruitment of CBL-514 Phase 2b study for Dercum’s disease has been initiated. The study results are anticipated in Q4 2025.

Caliway Completed CBL-514 Phase 2b Study for Subcutaneous Fat Reduction with Topline Result Expected in Q4 2024

Caliway announces that the CBL-0204 Phase 2b study was completed successfully at the end of May. The topline results are anticipated in Q4 2024.